Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jonathan W. Riess, Jacqueline V. Aredo et al.|JTO Clinical and Research Reports|2023Cited by 39
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.Jingran Ji, Jonathan W. Riess, Jacqueline V. Aredo et al.|Journal of Clinical Oncology|2020Cited by 18
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and CrizotinibJingran Ji, Jonathan W. Riess, Anupam Mitra et al.|Clinical Lung Cancer|2021Cited by 13
A phase II randomized placebo-controlled study of fisetin and exercise to mitigate chemotherapy-related functional decline in postmenopausal women with early breast cancer (PROFFi).Jingran Ji, Mina S. Sedrak, Catherine M. Crespi et al.|Journal of Clinical Oncology|2025Cited by 2
A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial designJingran Ji, Mina S. Sedrak, Catherine M. Crespi et al.|Therapeutic Advances in Medical Oncology|2026Cited by 1